Sex Differences in Cognitive Decline in Subjects with High Likelihood of Mild Cognitive Impairment due to Alzheimer's disease by Sohn, Dongwha et al.
1ScieNtific RepoRtS |  (2018) 8:7490  | DOI:10.1038/s41598-018-25377-w
www.nature.com/scientificreports
Sex Differences in Cognitive Decline 
in Subjects with High Likelihood of 
Mild Cognitive Impairment due to 
Alzheimer’s disease
Dongwha Sohn1,2, Katie Shpanskaya3, Joseph E. Lucas4, Jeffrey R. Petrella5, Andrew J. Saykin  6, 
Rudolph E. Tanzi7, Nagiza F. Samatova1,2 & P. Murali Doraiswamy8
Sex differences in Alzheimer’s disease (AD) biology and progression are not yet fully characterized. The 
goal of this study is to examine the effect of sex on cognitive progression in subjects with high likelihood 
of mild cognitive impairment (MCI) due to Alzheimer’s and followed up to 10 years in the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI). Cerebrospinal fluid total-tau and amyloid-beta (Aβ42) ratio 
values were used to sub-classify 559 MCI subjects (216 females, 343 males) as having “high” or “low” 
likelihood for MCI due to Alzheimer’s. Data were analyzed using mixed-effects models incorporating 
all follow-ups. The worsening from baseline in Alzheimer’s Disease Assessment Scale-Cognitive score 
(mean, SD) (9 ± 12) in subjects with high likelihood of MCI due to Alzheimer’s was markedly greater 
than that in subjects with low likelihood (1 ± 6, p < 0.0001). Among MCI due to AD subjects, the mean 
worsening in cognitive score was significantly greater in females (11.58 ± 14) than in males (6.87 ± 11, 
p = 0.006). Our findings highlight the need to further investigate these findings in other populations and 
develop sex specific timelines for Alzheimer’s disease progression.
Understanding the role of sex in health and disease is a cornerstone of personalized medicine1,2. The high failure 
rate of clinical drug trials in Alzheimer’s disease (AD) over the past decade3 has increased the urgency to better 
dissect the heterogeneity of AD4 in order to facilitate more personalized therapies. Females have been noted to 
be at the epicenter of the AD epidemic due to the fact that they account for roughly two-thirds of AD patients 
in the US and also the majority of caregivers1,5,6. However, despite substantial research investment in AD over 
decades, the biological role of sex in the neurodegenerative process has been relatively understudied. Laboratory 
research into AD mechanisms is largely done on male rodents - mirroring the sex bias that exists in many areas 
of biomedical research where findings from male animals are viewed as generalizable to humans of both sexes6.
The higher prevalence of AD in females was largely assumed to be due to their longer life spans compared to 
men but recent studies are beginning to paint a more complex picture1,5–23. In addition to lifespan differences, 
there are also well known sex differences in other possible AD risk factors such as in genetics, sex hormone 
changes in midlife, cognitive reserve, and age of onset of comorbid cardio metabolic diseases (reviewed in1,5,6) 
whose interactive effects remain poorly studied. Emerging evidence suggests that female sex may be linked to a 
greater effect of apolipoprotein ε4 allele (APOE ε4) on amyloid pathology and dementia risk as well as a faster rate 
of cognitive decline after onset of mild cognitive impairment (MCI) or AD10–17. In contrast, other studies note 
that men may have faster verbal memory decline in normal aging17, an earlier onset of cardiovascular disease, 
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greater risk for cerebral micro-hemorrhage10 and a higher risk for incident MCI18. Initial studies of pathological 
(e.g. beta-amyloid and tau measurements) and neuronal loss (e.g. hippocampal volumetric imaging) biomarkers 
has also suggested there may be sex differences in the evolution of AD pathophysiology1,13,20–23, reviewed in1 
and6. These findings, while preliminary, raise the possibility of multiple points of interaction between sex and AD 
progression.
The Alzheimer’s Disease Neuroimaging Initiative (ADNI), a multicenter, prospective, naturalistic study (www.
adni-info.org), conducted at sites in the US and Canada, has provided new insights into the timeline of evolution 
of AD biomarkers24–26. New NIA-AA recommendations for defining “MCI due to AD – high likelihood”27, which 
require positive pathological (molecular imaging or spinal fluid tests of beta-amyloid and tau) and/or neuronal 
loss (structural MR imaging) biomarkers in addition to clinical criteria, were, in part, based on MCI data from 
ADNI. However, these data have not yet been fully examined to study potential sex differences in the progression 
of subjects with MCI due to AD.
The aims of this study were to examine sex differences in the longitudinal cognitive progression of subjects 
with high likelihood of MCI due to AD.
Materials and Methods
Study Design. The institutional review board at Duke University Health System and at each site reviewed 
and approved all ADNI protocols. Prior to data collection, all subjects and their legal representatives, when appro-
priate, gave written informed consent.
Data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) (adni.loni.ucla.edu). ADNI was launched in 2003 as a large-scale public-private partnership 
with a primary goal to investigate whether the integration of clinical assessments, serial imaging studies, and 
other biological markers can be used to discover early signs of Alzheimer’s Disease (AD) progression. ADNI 
(ClinicalTrials.gov identifier: NCT00106899) involved over 60 sites across the United States and Canada. ADNI-1 
recruited approximately 400 MCI subjects and followed them up to 5 years. These subjects could then choose to 
continue in ADNI-2 and hence had total follow up of up to 10 years. ADNI-2 recruited approximately 150 new 
MCI subjects and followed them up to 5 years. Details of protocols and methods can be found in the procedures 
manual [www.adni-info.org].
Subjects. Subjects with late MCI enrolled in ADNI-1 and ADNI-2 were eligible for inclusion in this study and 
were pooled for analyses. All late MCI subjects were between the ages of 55 and 90, had subjective memory com-
plaint, objective memory deficit documented by the Wechsler Memory Scale Logical Memory II, and a Clinical 
Dementia Rating (CDR) Global of 0.5, did not meet criteria for dementia and had a Geriatric Depression Scale 
score of less than 6. The diagnostic criteria for late MCI were identical between ADNI-1 and ADNI-2 (http://adni.
loni.usc.edu/methods/documents). All subjects met criteria for late MCI. All ADNI-1 and ADNI-2 MCI subjects 
with at least one post-baseline visit data were eligible for inclusion. In addition to demographic data, for subject 
inclusion, data for all the following parameters were required: Alzheimer’s Disease Assessment Scale-Cognitive 
subscale 11 item (ADAS-Cog11) for at least two different time points, APOE ε4 genotyping results, and biomarker 
data. The term “baseline” is used to indicate data collected first at either screening or baseline. The definition of 
the subset of subjects with a high likelihood of “MCI due to AD” is described under Cerebrospinal fluid (CSF) 
methods.
Demographic and Clinical Variables. Demographic variables included were age, sex, education level. 
Cognitive variables included the ADAS-Cog11 and Mini Mental State Examination (MMSE) [http://www.
adni-info.org/].
APOE ε4 Genotyping. APOE ε4 allele genotyping of all subjects was completed using DNA extracted from 
peripheral blood cells as detailed previously28.
MRI Hippocampal Volume Measures. Hippocampal volumes for each subject at baseline were extracted 
from structural MRI brain scans acquired using a standardized protocol and an automated pipeline using 
FreeSurfer software (https://surfer.nmr.mgh.harvard.edu/)25,29. For this report, only baseline total (right plus left) 
hippocampal volumes (mm3) were used25.
Cerebrospinal fluid (CSF) Assay. Baseline CSF total tau (t-tau), phosphorylated tau181P (p-tau), 
and amyloid-beta1–42 (Aβ42) were analyzed by the ADNI Biomarker Core Laboratory at the University of 
Pennsylvania Medical Center using the multiplex xMAP Luminex platform (Luminex Corp) with Innogenetics 
(INNO-BIA AlzBio3, for research use–only reagents) immunoassay kit–based reagents (www.adni-info.org). CSF 
data was available for approximately one-half of ADNI-1 subjects and most of ADNI-2 subjects. Based on t-tau/
Aβ42 ratio values, MCI subjects were sub-classified as having “high” (>0.395 cut-off) or “low” (<0.394 cut-off) 
likelihood of meeting criteria for MCI due to Alzheimer’s26.
Longitudinal Cognitive tests. MCI subjects were monitored in both ADNI-1 and ADNI-2 at 12 month 
intervals for up to 5 years. In addition, ADNI-1 MCI subjects could be followed for an additional 5 years if they 
chose to continue into ADNI-2 thus had a maximum possible follow up of 10 years. At each annual follow visit, 
subjects underwent cognitive assessments [http://www.adni-info.org/].
Statistical Analysis. We pooled MCI subjects from ADNI-1 and ADNI-2 studies. Sex-differences in base-
line demographic and cognitive variables were tested using either analysis of variance (ANOVA) or analysis of 
covariance (ANCOVA).
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Next we ran three mixed-effect models to examine the effect of sex on change from baseline in ADAS-Cog11. 
The first model adjusted for age, education, baseline ADAS-Cog11, and APOE ε4 allele status as follows:
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In this model, the follow-up time (month) was centered with the median follow-up time and covariates were 
centered i.e. a 75 years old APOE ε4- male with 16 years of education and an ADAS-Cog11 score of 11. We 
included both random slope and random intercept of each subject in this mixed effect model to account for 
subject-specific variability in each baseline dependent variable and rate of change, respectively, as reported pre-
viously14. Square root transformations were used for all dependent variables in all models to obtain approximate 
normality of estimated error distribution and homoscedasticity (constant variance) of the errors across fitted 
values of each dependent variable. In the models, APOE ε4 status was treated as a categorical variable while 
age, education, cognitive scores were treated as continuous variables. In the equation, APOE ε4 ++ indicates 
carriers of two APOE ε4 alleles (homozygous) while APOE ε4 + indicates carriers of one APOE ε4 allele (hete-
rozygous). We also ran a second mixed effect model replacing APOE ε4 with biomarkers (baseline t-tau, Aβ42 or 
hippocampal volume) as covariates. Next, we ran a mixed effects model in subjects with high likelihood of MCI 
due to AD selected two ways. The first was based on high t-tau/Aβ42 ratio. In this model, APOE ε4 status was 
not included as a term in this last model due to its collinearity with Aβ42. We also ran a mixed effects model in 
MCI subjects who are APOE ε4 positive. The model terms and covariates are all described in the Tables. Not all 
analyses had the same sample sizes due to missing values or drop outs. All statistical analyses were conducted in 
the R (www.r-project.org); mixed-effect models for longitudinal analyses were conducted using the nlme package 
in the R. All methods were performed in accordance with the relevant guidelines and regulations.
ADNI MCI All Female Male p-value
No. subjects 559 216 343
Age (years) 74.0/7.5 72.8/7.6 74.8/7.4 0.002
Education (years) 15.9/2.9 15.4/2.8 16.2/3.0 0.004
MMSE 27.2/1.8 27.1/1.8 27.2/1.8 0.492
ADAS-Cog11 11.5/4.6 11.2/4.8 11.7/4.4 0.158
APOE ε4 carriers (%) 54 58 52 0.196
MCI due to AD – high likelihood (%) 69.5 73.0 67.3
Follow-up Duration (months) 43.8/29.6* 42.4/27.3* 44.8/30.9* 0.351
Total hippocampal volume (mm3) 5901.1/ 1079.3 (n = 443)
5678.9/1073.5 
(n = 168)
6036.9/ 1062.0 
(n = 275) <0.001
“MCI due to AD – high likelihood” All Female Male p-value
No. subjects 244 100 144
Age (years) 73.6/7.3 71.3/7.2 75.1/6.9 <0.001
Education (years) 16.1/2.8 15.5/2.8 16.5/2.8 0.006
MMSE 27.0/1.8 26.9/1.8 27.0/1.9 0.663
ADAS-Cog11 12.6/4.9 12.3/4.9 12.8/4.8 0.511
APOE ε4 carrier (%) 70 76 65 0.098
Follow-up Duration (months) 40.4/24.8 38.7/22.9 39.7/27.0 0.770
Total hippocampal volume (mm3) 5773.4/1006.0 (n = 184)
5622.2/1011.4 
(n = 77)
5882.2/992.6 
(n = 107) 0.084
Table 1. Baseline Demographic and Clinical Characteristics by Sex of Subjects. ANOVA (Analysis of variance) 
assessed differences in age, education year, follow-up duration and ANCOVA (Analysis of covariance) assessed 
sex-differences in baseline MMSE and ADAS-Cog11 scores adjusting for age, years of education. Data are 
expressed as mean/standard deviation, as appropriate. Bold p-values are statistically significant. Abbreviations: 
AD (Alzheimer’s disease), MCI (mild cognitive impairment), ADAS-Cog11 (Alzheimer’s disease assessment 
scale- cognitive subscale), MMSE (mini- mental state examination), and APOE ε4 (apolipoprotein ε4 allele). 
Follow-up duration is calculated based on ADAS-Cog 11 measurement. CSF t-tau/Aβ42 ratio cut-offs were used 
to classify subjects as having “high” likelihood of meeting criteria for “MCI due to AD”. See text for details.
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Results
Table 1 summarizes the baseline demographics of the 559 MCI subjects included in this study. Female subjects 
were younger than male MCI subjects (p = 0.002). There was no statistically significant difference in APOE ε4 
carrier status between males and females.
Effect of sex on longitudinal cognitive decline. Mean follow up duration (months) for males 
(44.8 ± 30.9) did not significantly differ from that of females (42.4 ± 27.3). The mean (±SD) change from baseline 
in ADAS-Cog11 in females (8.7 ± 12.6) was greater than in males (5.8 ± 10.1, p = 0.001). The mean change from 
baseline in ADAS-Cog11 in female APOE ε4 carriers (10 ± 14) and non-carriers (7 ± 10) was greater than in male 
APOE ε4 carriers (8 ± 11) (p = 0.04) and non-carriers (3 ± 9) (p = 0.003), respectively.
Table 2 depicts the mixed effects model testing for sex and APOE ε4 effects on longitudinal change in 
ADAS-Cog11 in MCI subjects. In this model, sex had a significant effect on ADAS-Cog11 slope (p = 0.003) with 
the cognitive decline being greater in females than males. Baseline cognition, education and APOE ε4 status also 
had a significant effect. Subjects with worse baseline cognition and higher education declined faster. APOE ε4 
heterozygotes and homozygotes declined faster, and APOE ε4 had a significant effect on both slope and curva-
ture of ADAS-Cog11 change (compared to non-carriers). The effect of interaction between sex and APOE ε4 on 
ADAS-Cog11 change was not significant (Supplementary Table 1).
Table 3 depicts the mixed effects model testing the effect of sex and baseline CSF Aβ42 (as a continuous meas-
ure) on longitudinal change in ADAS-Cog11 in MCI subjects. In this model, sex (p = 0.027), baseline CSF Aβ42 
(p < 0.001) had a significant effect on ADAS-Cog11 change. Females and subjects with lower CSF Aβ42 declined 
faster. Aβ42 also had a significant effect on curvature of ADAS-Cog11 change (p < 0.001). The effect of age, educa-
tion, baseline cognition was not significant. Supplementary Table 2 depicts the effect of sex and baseline CSF t-tau 
on ADAS-Cog11 change. In this model, the effect of sex was not significant but patients with higher CSF t-tau had 
greater ADAS-Cog11 worsening (p < 0.001). Supplementary Table 3 depicts the effect of sex and baseline total 
hippocampal volume on ADAS-Cog11 change. Baseline total hippocampal volumes were smaller in females (than 
males). However, when normalized as a ratio to intracranial volume, they were significantly larger than that of 
males. In the mixed model of ADAS-Cog11 change, the effect of sex was not significant but the effect of baseline 
total hippocampal volume was significant (p < 0.0001).
Sex differences in Subjects with High Likelihood of MCI due to AD. As described in Methods, we used 
t-tau/Aβ42 ratio cut-off to identify subjects with “MCI due to AD – high likelihood”. 70% of all MCI subjects, 73% 
of females and 67% of males met this criterion for MCI due to AD (Table 1). The mean (±SD) change from baseline 
Term Coefficient Standard error t-value p-value
Intercept 3.544899 0.06782345 52.26658 <0.001
Sex effect 0.255545 0.08529762 2.99592 0.003
APOE ε4 + effect 0.308539 0.08876979 3.47572 <0.001
APOE ε4 +  + effect 0.568898 0.13237472 4.29763 <0.001
Baseline rate 0.012660 0.00181201 6.98689 <0.001
Baseline curvature 0.000099 0.00001834 5.39852 <0.001
Age effect 0.011337 0.00560956 2.02101 0.044
Education effect 0.016933 0.01428969 1.18500 0.237
Baseline cognition effect 0.166261 0.00932751 17.82485 <0.001
Female effect on slope 0.006905 0.00231191 2.98663 0.003
Female effect on curvature 0.000006 0.00002605 0.24503 0.807
APOE ε4 + effect on slope 0.010323 0.00238571 4.32693 <0.001
APOE ε4 + + effect on slope 0.018991 0.00362755 5.23525 <0.001
APOE ε4 + effect on curvature 0.000071 0.00002589 2.76107 0.006
APOE ε4 + + effect on curvature 0.000115 0.00004004 2.87349 0.004
Education effect on slope 0.000780 0.00038381 2.03293 0.042
Age effect on slope 0.000142 0.00015109 0.94080 0.347
Baseline cognition effect on slope 0.001074 0.00025382 4.23056 <0.001
Table 2. Effect of Sex and APOE ε4 on longitudinal change in ADAS-Cog11 of MCI subjects. Baseline 
cognition indicates ADAS-Cog 11. Bold p-values are statistically significant. Abbreviations: MCI (mild 
cognitive impairment), ADAS-Cog11 (Alzheimer’s disease assessment scale- cognitive subscale), and APOE ε4 
(apolipoprotein ε4 allele). In this model, the follow-up time (month) was centered with the median follow-up 
time (36 months) and covariates were centered i.e. a 75 years old APOE ε4- male with 16 years of education 
and an ADAS-Cog11 of 11. Table depicts that the effect of sex on ADAS-Cog11 change was significant with 
females declining faster than males. Education and baseline cognition also had significant effects. The intercept 
is a term to get the correct estimate of the outcome when time = 0. The baseline rate is the reference population 
rate of change in the outcome starting at time zero, and the baseline curvature is the “acceleration” of that rate 
of change at time zero. The upper half of the table shows the effect of specific variables on ADAS-Cog11 and the 
bottom half shows their effects on ADAS-Cog11 slope and curvature.
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in ADAS-Cog11 (9 ± 12) in subjects with “MCI due to AD – high likelihood” subjects was significantly greater than 
that in MCI subjects who did not meet such criteria (1 ± 6, p < 0.0001). Among subjects with “MCI due to AD – high 
likelihood”, the mean worsening in ADAS-Cog11 was significantly greater in females (12 ± 14) than in males (7 ± 11, 
p = 0.006) (Figs 1 and 2). Table 4 depicts the mixed effects model testing the effect of sex on ADAS-Cog11 change in 
subjects with MCI due to AD – in this model, the effect of sex was significant on ADAS-Cog11 slope (p = 0.021). In 
this model, age, education and baseline cognition did not have a significant effect.
Figure 1. ADAS-Cog11 change in subjects with high or low probability of MCI due to AD. Y-axis depicts the 
mean (SE) change from baseline in ADAS-Cog11 of MCI subjects by sex. X-axis depicts the grouping by CSF t-tau/
Aβ42 ratio into “high” or “low” likelihood of having MCI due to AD. MCI due to AD high probability subjects had 
greater change than those with low probability. Among subjects with high probability of MCI due to AD, females 
showed greater change than males. Data comprises pooled MCI subjects from ADNI-1 and ADNI-2.
Term Coefficient Standard error t-value p-value
Intercept 3.877795 0.06891898 56.26600 <0.001
Sex effect 0.223058 0.10668516 2.09081 0.037
Aβ42 effect −0.007031 0.00100517 −6.99508 <0.001
Baseline rate 0.023720 0.00184203 12.87688 <0.001
Baseline curvature 0.000177 0.00002078 8.52360 <0.001
Age effect 0.002999 0.00680578 0.44068 0.660
Education effect 0.000530 0.01816607 0.02918 0.977
Baseline cognition effect 0.139866 0.01143890 12.22720 <0.001
Female effect on slope 0.006420 0.00290663 2.20866 0.027
Female effect on curvature −0.000006 0.00003607 −0.15359 0.878
Baseline Aβ42 effect on slope −0.000216 0.00002632 −8.21396 <0.001
Baseline Aβ42 effect on curvature −0.000001 0.00000028 −3.52631 <0.001
Education effect on slope 0.000301 0.00048418 0.62259 0.534
Age effect on slope −0.000006 0.00018281 −0.03192 0.975
Baseline cognition effect on slope 0.000378 0.00030937 1.22315 0.221
Table 3. Effect of Sex and CSF Aβ42 on longitudinal change in ADAS-Cog11 of MCI subjects. Baseline 
cognition indicates ADAS-Cog 11. Bold p-values are statistically significant. Abbreviations: MCI (mild 
cognitive impairment), ADAS-Cog11 (Alzheimer’s disease assessment scale- cognitive subscale), and Aβ42 
(amyloid-beta1–42). In this model, the follow-up time (month) was centered with the median follow-up time (36 
months) and covariates were centered i.e. a 75 years old with 16 years of education, ADAS-Cog11 of 11, and 
Aβ42 of 147. Table depicts that the effect of sex on ADAS-Cog11 slope was significant with females declining 
faster than males. Baseline Aβ42 also had a significant effect on both slope and curvature. Age and education 
did not have significant effects on slope. The intercept is a term to get the correct estimate of the outcome when 
time = 0. The baseline rate is the reference population rate of change in the outcome starting at time zero, and 
the baseline curvature is the “acceleration” of that rate of change at time zero. The upper half of the table shows 
the effect of specific variables on ADAS-Cog11 and the bottom half shows their effects on ADAS-Cog11 slope 
and curvature.
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Sex differences in APOE ε4 positive MCI subjects. Table 5 depicts results of a mixed effect model 
testing for sex differences in ADAS-Cog11 change over time in APOE ε4 positive MCI subjects (including both 
heterozygotes and homozygotes). In this model, sex had a near significant effect on ADAS-Cog11 slope (p = 0.05) 
with the cognitive decline being greater in females than males.
ADNI-1 versus ADNI-2. Supplementary Figures 1 and 2 depict the mean change from baseline to last obser-
vation as well as the slopes (derived from a simple quadratic model) of ADAS-Cog11 change in males and females 
in ADNI-1 and ADNI-2 separately for subjects with MCI due to AD high probability. Of the overall MCI sample, 
there were 397 from ADNI-1 and 162 from ADNI-2. The mean follow up of ADNI-1 subjects was 48.2 and for 
ADNI-2 subjects was 33.2. In both ADNI-1 and ADNI-2, MCI due to AD high probability subjects declined 
much faster than biomarker negative subjects (Supplementary Figures 1 and 2). Among MCI due to AD subjects, 
significant longitudinal sex differences were seen in ADNI-1 MCI but not in ADNI-2.
Figure 2. ADAS-Cog11 Slopes in subjects with high or low probability of MCI due to AD. X-axis depicts 
maximum duration of follow up. Y-axis depicts ADAS-Cog11 scores. MCI subjects have been grouped 
using CSF t-tau/Aβ42 ratio as having “high” or “low” probability of MCI due to AD. Slopes and confidence 
intervals are derived from a simple quadratic model (polynomial regression) by sex over time without any 
other covariates. Data comprises pooled MCI subjects from ADNI-1 and ADNI-2. Female subjects with high 
probability of MCI due to AD showed greater decline than the other groups.
Term Coefficient Standard error t-value p-value
Intercept 3.964566 0.09028821 43.91011 <0.001
Sex effect 0.384134 0.14181187 2.70876 0.007
Baseline rate 0.026903 0.00255143 10.54425 <0.001
Baseline on curvature 0.000196 0.00002650 7.41382 <0.001
Age effect 0.005377 0.00955933 0.56247 0.574
Education effect 0.026654 0.02443509 1.09082 0.277
Baseline cognition effect 0.131962 0.01403214 9.40425 <0.001
Female effect on slope 0.009472 0.00410204 2.30907 0.021
Female effect on curvature −0.000003 0.00004764 −0.07276 0.942
Education effect on slope 0.000881 0.00068796 1.28007 0.201
Age effect on slope −0.000066 0.00026925 −0.24662 0.805
Baseline cognition effect on slope 0.000246 0.00039833 0.61665 0.538
Table 4. Effects of Sex on ADAS-Cog11 change in MCI due to AD – high likelihood. CSF t-tau/Aβ42 ratio 
was used to identify subjects with MCI due to AD – high likelihood. Baseline cognition indicates ADAS-Cog 
11. Bold p-values are statistically significant. Abbreviations: MCI (mild cognitive impairment), ADAS-Cog11 
(Alzheimer’s disease assessment scale- cognitive subscale). In this model, the follow-up time (month) was 
centered with the median follow-up time (36 months) and covariates were centered i.e. a 75 years old with 16 
years of education and an ADAS-Cog11 of 11. The effect of sex was significant with females declining faster 
than males. The intercept is a term to get the correct estimate of the outcome when time = 0. The baseline rate 
is the reference population rate of change in the outcome starting at time zero, and the baseline curvature is the 
“acceleration” of that rate of change at time zero. The upper half of the table shows the effect of specific variables 
on ADAS-Cog11 and the bottom half shows their effects on ADAS-Cog11 slope and curvature.
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Discussion
Understanding the potential underpinnings of sex-related differences in the risk for dementia is an important 
research priority for the field1–7. Our study systematically examined sex differences in longitudinal cognitive 
outcomes using pooled MCI data from two multicenter studies, ADNI-1 and ADNI-2. To our knowledge, this 
is also the first report to examine sex differences in outcomes of MCI subjects defined using pathological CSF 
biomarkers to have a high likelihood for MCI due to Alzheimer’s.
Several interesting findings emerged from this study. Our longitudinal cognitive analyses of the pooled dataset 
found that MCI females showed greater cognitive decline than males. Our study also found that APOE ε4 has an effect 
on both slope and curvature of ADAS-Cog11 decline and with both heterozygotes and homozygotes declining faster 
than non-carriers. Further among MCI APOE ε4 carriers, we found that females declined faster than males. We found 
no interaction effect between sex and APOE ε4 suggesting these variables may potentially have additive but not multi-
plicative effects. Lastly, we used CSF biomarkers to identify subjects with “high” or “low” probability of having MCI due 
to AD. Although not a perfect classifier, the tau/Aβ42 ratio cut-off we used has been validated in a clinic-pathological 
study25, used in published studies e.g.30,31, and cited in the NIA-AA guideline report on diagnosing MCI due to AD27. 
Approximately 70% of the ADNI MCI sample met these surrogate criteria for “MCI due to AD – high likelihood”. MCI 
due to AD subjects showed a markedly greater cognitive decline (almost 9-fold) than MCI subjects not meeting these 
criteria. This further supports the utility of the CSF ratio as a potential prognostic marker for selecting subjects at high 
risk for decline in clinical trials. Further, among the “MCI due to AD – high likelihood” group, females showed greater 
cognitive decline than males. This finding extends prior reports of sex differences in MCI13,14,23 and to our knowledge is 
the first study to examine sex differences in subjects with “MCI due to AD – high likelihood”.
There are some strengths and limitations to our study. A major strength of the ADNI study data is that it 
represents a multicenter biomarker study that recruited subjects from over 60 sites in the US and Canada and 
performed longitudinal clinical and biomarker assessments using a highly standardized protocol24. ADNI results 
have, in part, formed the basis for entry criteria in many prevention trials and hence ADNI is a highly relevant 
dataset. Our analyses tried to mimic the emerging new criteria for MCI due to AD – high likelihood using patho-
logical CSF biomarkers. There is as such no definitive binary marker for neuronal loss and hence we relied on 
pathological markers. The relatively large sample size and long duration of follow up are other strengths of the 
analyses. There are also some limitations. ADNI subjects were recruited largely at clinic-based research sites for 
a biomarker study and as such may not reflect milder subjects seen in general practice, especially in primary 
care settings. While we relied on a pathologically validated25 tau/Aβ42 ratio cut-off as a surrogate to identify 
biomarker positive MCI subjects, there is as yet no perfect in-vivo method to identify MCI due to AD. While 
the diagnostic utility of CSF tau/Aβ42 ratio may differ by setting and laboratory32, it still remains useful for 
identifying a subset of rapid decliners. While baseline sex differences were seen in both studies, longitudinal sex 
differences were driven primarily by ADNI-1 data and were not significant in ADNI-2. We do not know why, 
but one possibility may be that ADNI-1 recruited twice as many MCI subjects as ADNI-2 and ADNI-1 subjects 
could have a 120 month maximum follow up (versus 60-month maximum follow up in ADNI-2). Although entry 
criteria were the same for late MCI between ADNI-1 and ADNI-2, we cannot rule out the possibility of selection 
bias since the two studies were done 5 years apart. Differences in comorbid conditions and concomitant medica-
tions between ADNI studies may also have contributed. Since the follow up period was roughly the same between 
males and females, the observed differences are less likely to be due to attrition or survival biases but we cannot 
rule them out. We studied sex effects on the ADAS-Cog11 as it is frequently used in clinical trials. However, it is 
not necessarily perfectly balanced across all cognitive domains and there is some evidence that females may show 
Term Coefficient Standard error t-value p-value
Intercept 3.922808 0.07839959 50.03608 <0.001
Sex effect 0.330213 0.12658675 2.60859 0.010
Baseline rate 0.025747 0.00213309 12.07038 <0.001
Baseline on curvature 0.000199 0.00002031 9.79324 <0.001
Age effect 0.017849 0.00888039 2.00998 0.045
Education effect 0.034823 0.02094617 1.66248 0.098
Baseline cognition effect 0.155364 0.01336529 11.62443 <0.001
Female effect on slope 0.006926 0.00353623 1.95851 0.050
Female effect on curvature −0.000029 0.00003745 −0.78379 0.433
Education effect on slope 0.001089 0.00057509 1.89437 0.058
Age effect on slope 0.000240 0.00024422 0.98105 0.327
Baseline cognition effect on slope 0.001011 0.00037038 2.72871 0.006
Table 5. Effects of Sex on ADAS-Cog11 change in MCI APOE ε4 carriers. Baseline cognition indicates 
ADAS-Cog 11. Bold p-values are statistically significant. Abbreviations: MCI (mild cognitive impairment), 
ADAS-Cog11 (Alzheimer’s disease assessment scale- cognitive subscale). In this model, the follow-up time 
(month) was centered with the median follow-up time (36 months) and covariates were centered i.e. a 75 years 
old with 16 years of education and an ADAS-Cog11 of 11. The effect of sex on ADAS-Cog11 slope was near 
significant. The intercept is a term to get the correct estimate of the outcome when time = 0. The baseline rate 
is the reference population rate of change in the outcome starting at time zero, and the baseline curvature is the 
“acceleration” of that rate of change at time zero. The upper half of the table shows the effect of specific variables 
on ADAS-Cog11 and the bottom half shows their effects on ADAS-Cog11 slope and curvature.
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a slightly different profile (as a group) than males on this test. To rule out potential testing bias, it is important to 
also examine sex differences on other cognitive and functional domains. Hence, these issues must be kept in mind 
while interpreting the data and our findings must be viewed as initial pending replication in population samples.
Our study does not directly address mechanisms that may underlie potential sex differences in MCI pro-
gression. Theories proposed have included a greater potency of the AD risk associated with the APOE ε4 allele 
and the BDNF Met66 allele in females, differences in sex hormones, smaller head size, lower cognitive reserve, 
as well as the possibility of differential expression of a variety of genes (reviewed in1,5–23). The disappearance of 
sex effects after co-varying for total hippocampal volumes and total tau levels suggest these may be somehow 
related. However, because AD involves multiple biochemical alterations, systems biology approaches to examine 
sex differences at a network and pathway level are warranted and may yield deeper insights28,33,34. In summary, 
our findings of sex differences in both baseline biomarkers and cognitive progression in biomarker defined MCI 
subjects highlight the need to further investigate sex specific biomarker evolution and disease progression in AD.
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